Business Context and Reporting Period
Company: National Research Corporation (NRC Health)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2004
Business Overview: NRC Health provides survey-based performance measurement, analysis, and improvement services to the healthcare industry. Primary services include performance tracking, custom research, educational services, and the Healthcare Market Guide. The company expanded into Canada in 2003 via the acquisition of Smaller World Communications Inc.
Key Financial Metrics
| Metric | Q1 2004 | Q1 2003 |
|---|---|---|
| Revenues | $7,561,316 | $6,057,867 |
| Operating Income | $1,895,118 | $1,512,293 |
| Net Income | $1,175,198 | $920,595 |
| Diluted EPS | $0.16 | $0.13 |
| Operating Margin | 25.1% | 24.9% |
| Net Cash from Operations | $3,728,148 | $2,595,054 |
| Cash and Equivalents (End of Period) | $5,226,501 | $1,257,424 |
| Working Capital | $16,200,088 | N/A |
| Total Debt (Notes Payable) | $5,008,429 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 24.8% to $7.6 million, driven by new client contracts sold in 2003 and expanded scope with existing clients.
- Expense Trends:
- Direct Expenses: Increased 17.1% to $3.3 million due to labor, printing, and fieldwork costs. However, as a percentage of revenue, this decreased from 46.5% to 43.6% due to margin expansion.
- Selling, General & Administrative (SG&A): Increased 48.2% to $1.9 million, primarily due to salary/benefit increases ($469k), marketing ($65k), and recruitment ($49k) to support sales expansion.
- Cash Flow: Net cash provided by operating activities rose to $3.7 million (from $2.6 million), aided by a decrease in trade accounts receivable and an increase in accounts payable.
- Investing Activities: Net cash used in investing activities decreased significantly to $768,000 (from $2.3 million) as the prior year included a $961,000 acquisition payment not present in the current period.
- Financing Activities: The company used $1.2 million in financing activities, primarily for the repurchase of treasury stock ($1.2 million), compared to a net inflow of $14,000 in the prior year.
Guidance, Outlook, and Risks
- Outlook: Management expects direct expenses to increase slightly for the remainder of 2004 to align with 2003 margins. SG&A expenses as a percentage of revenue are expected to decrease as revenues grow. Depreciation and amortization as a percent of revenue are expected to decrease slightly.
- Stock Repurchase Program: Under a July 2003 authorization, the company has repurchased 30,200 shares as of May 4, 2004, with authority to repurchase an additional 486,000 shares. The 1999 authorization is fully utilized.
- Deferred Revenue: The company holds $4.2 million in billings in excess of revenues earned (deferred revenue), which is expected to be recognized within 12 months.
- Risks/Contingencies: No material changes in market risk exposures were reported. The company confirmed it has no interest in variable interest entities subject to FIN 46.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 24.8% revenue growth and the mix of new client contracts versus cross-selling.
- Expense Management: Monitor SG&A expenses, which rose 48.2%; confirm if the projected decrease in SG&A as a percentage of revenue materializes in subsequent quarters.
- Cash Conversion: Review the significant reduction in trade accounts receivable ($2.1 million improvement in cash flow) to ensure it is not a one-time collection event.
- Capital Allocation: Assess the impact of the $1.2 million treasury stock repurchase on liquidity and future capital needs.
- Deferred Revenue: Track the recognition of the $4.2 million deferred revenue balance to ensure it converts to revenue as expected.